54 results
6-K
EX-99.1
ALVO
Alvotech
14 Jun 24
Cautionary Note Regarding Forward Looking Statements
4:36pm
to market around the world; a purpose-built biosimilars research and development and manufacturing platform; commercial partnerships in global markets … to the recognition of a $6.5 million research and development milestone due to the approval of AVT04 in Europe and $16.8 million relative to research
424B5
ALVO
Alvotech
14 Jun 24
Prospectus supplement for primary offering
4:30pm
team that has brought numerous successful biologics and biosimilars to market around the world; a purpose-built biosimilars research and development … actual expenditures will depend upon numerous factors, including the results of our research and development efforts, the timing and success
6-K
EX-99.1
ALVO
Alvotech
22 May 24
Alvotech Reports Financial Results for First Quarter of 2024 and Provides a Business Update
6:30am
, 2023. The license and other revenue of $24.4 million was primarily attributable to the recognition of a $6.5 million research and development … milestone due to the approval of AVT04 in Europe and $16.8 million relative to research and development milestone due to the CTA submission for the AVT16
6-K
EX-99.1
ALVO
Alvotech
21 May 24
Current report (foreign)
8:41am
such products could be affected by, among other things, the uncertainties inherent in research and development, including clinical trial results
6-K
EX-99.2
7hw7j
20 Mar 24
Alvotech Reports Financial Results for Full Year 2023 and Provides a Business Update
4:30pm
6-K
EX-99.1
04j0em
20 Mar 24
Alvotech Reports Financial Results for Full Year 2023 and Provides a Business Update
4:30pm
6-K/A
EX-99.1
9ujbn w6rcbajjkljhi
30 Nov 23
Alvotech Reports Financial Results for First Nine Months of 2023 and Provides a Business Update
9:19am
6-K
EX-99.1
0vt w4xbn4
29 Nov 23
Alvotech Reports Financial Results for First Nine Months of 2023 and Provides a Business Update
7:00am
F-3
jwygdmnad
20 Oct 23
Shelf registration (foreign)
4:06pm
6-K/A
EX-99.1
9yxs 90nrhsn4zp4g
7 Sep 23
Current report (foreign) (amended)
1:06pm
6-K
EX-99.1
j3a88hupkx17v9g
31 Aug 23
Current report (foreign)
8:00am
6-K
EX-99.8
0sb7uchtzw42a 87
31 Aug 23
Current report (foreign)
8:00am
6-K
EX-99.2
spoy bj17gb
31 Aug 23
Current report (foreign)
8:00am
6-K
EX-99.1
8u7v qyum
19 May 23
Alvotech Reports Financial Results for First three Months of 2023
11:54am
424B3
dzwct6
17 Nov 22
Prospectus supplement
5:21pm
424B3
9m6l8z cm0fe8hb
17 Nov 22
Prospectus supplement
5:21pm
6-K
EX-99.9
i2d6 3c6jhyhs14b
17 Nov 22
Alvotech Secures Financing Facilities of Approximately $136 Million
5:18pm
6-K
EX-99.5
cz7isn otp8h
17 Nov 22
Alvotech Secures Financing Facilities of Approximately $136 Million
5:18pm
6-K
EX-99.4
f2vx9m8utbbgs8w
17 Nov 22
Alvotech Secures Financing Facilities of Approximately $136 Million
5:18pm